Hera BioLabs is a contract research organization (CRO) utilizing gene editing technologies to create enabling preclinical research models for oncology & immuno-oncology. Hera’s platform model, the OncoRat SRG, is a SCID rat on the Sprague-Dawley background harboring a double knockout for the Rag2 and Il2rgamma genes. This enhanced immunodeficient rat model has a severely impaired immune system lacking B-cells, T-cells, and NK-cells. The OncoRat overcomes limitations of mouse models for xenograft efficacy studies. For example, the OncoRat enables tumor cell line xenograft models that were previously inefficient or not feasible in mouse models. While the long timeline required for the establishment of patient derived xenografts or PDX models in mice is often impractical; the OncoRat grows ~10x larger tumors enabling PDX establishment and efficacy studies in fewer passages and a shorter amount of time. Oncology efficacy studies (xenograft and PDX) include prostate cancer and NSCLC. The SRG is currently being developed with a humanized immune system for immuno-oncology studies.
SD Rag2 Il2rg Knockout Rat (SRG Rat)
The SRG rat (SD-Rag2tm2hera - Il2rgtm1hera ), contains a knockout of both the Rag2 and Il2rg genes on the Sprague Dawley background. This newly created immunodeficient rat model has a severely impaired immune system lacking B-cells, T-cells, and NK-cells. The SRG rat overcomes the limitations of less immunodeficient rat models and provides enhanced utility in comparison to immunodeficient mouse models including demonstrating high tumor take rates and favorable growth kinetics for both xenografts and PDX models.
Xenograft/PDX efficacy studies conducted in our newly created SRG rat model or other immunodeficient rodent strains.
--Basic Study Outline--
Species/Strain: SGR rat, and/or Mice.
Tumors Cells: Client specified
Tumor Implantation: Subcutaneous
Dosing Method: Oral Gavage
Study Length: 28 days
Study Groups: 5-arms (3 TAs and a positive and negative control groups)
Each study is fully customize-able to meet your needs, including implantation type, dosing method, a variety of measurements and endpoints. Additional toxicology or PK endpoints can be added to the study as well.
Total Estimated Timeline: 6 weeks
Why use SRG rats for xenograft studies?
Hera BioLabs has not received any reviews.
Hera BioLabs has not received any endorsements.